Can venetoclax cure leukemia and how does it work?

Venetoclax is an anti-tumor targeted drug, and its application in the field of leukemia treatment has aroused widespread discussion. However, we need to be clear about whether it can cure leukemia.

First of all, venetoclax does not guarantee a complete cure for leukemia, but it does control the progression of the disease to a certain extent and improve the patient's quality of life. Its principle of action is mainly based on inhibiting the function ofB-cell lymphoma-2 (BCL-2) protein. The BCL-2 protein plays a key role in some leukemias and other cancers, preventing cancer cells from the natural death process known as apoptosis. Venetoclax selectively binds to BCL-2 protein to restore the normal apoptosis mechanism of cells, thereby inducing cancer cell death and achieving anti-tumor effects.

Specifically, after venetoclax enters cells, it will bind tightly toBCL-2 protein and block its anti-apoptotic effect. This causes cancer cells that were originally "protected" by the BCL-2 protein to lose their shelter and be exposed to apoptotic signals again. As cancer cells gradually move toward apoptosis, tumor growth and spread are effectively controlled.

It is worth noting that although venetoclax has achieved certain results in the treatment of leukemia, not all types of leukemia are sensitive to it. In addition, the treatment of leukemia usually requires a comprehensive consideration of multiple methods, such as chemotherapy, radiotherapy, immunotherapy, etc. Therefore, venetoclax is more of a part of a leukemia treatment regimen than a single "miracle drug."

Overall, venetoclax plays a positive role in the treatment of leukemia through its unique mechanism of action. However, it alone does not guarantee complete cure of leukemia. When choosing a treatment plan, patients should fully understand the working principle and possible efficacy of the drug, and carry out standardized treatment under the guidance of a doctor.